Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The P2X7 Receptor: A Key Player in Immune-Mediated Bone Loss?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Predictors of effects of lifestyle intervention on diabetes mellitus type 2 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Advanced HCC is a clinical challenge with limited treatment options. The multikinase inhibitor sorafenib is the first and only agent showing a survival benefit in these patients. In this study we evaluate the efficacy and tolerability of sorafenib in an unselected patient population. Furthermore we explore the role of alpha-fetoprotein (αFP) as a potential biomarker for treatment efficacy and correlation to survival.
OriginalsprogEngelsk
TidsskriftTheScientificWorldJournal
Vol/bind2013
Sider (fra-til)931972
ISSN1537-744X
DOI
StatusUdgivet - 2013

ID: 42236579